Prognostic Significance of CD56 Antigen Expression in Patients with <i>De Novo</i> Non‐M3 Acute Myeloid Leukemia

Sun, Yanni; Wan, Jia; Song, Qifan; Luo, Can; Li, Xi; Luo, Yun Mei; Huang, Xiangtao; Ding, Ruiheng; Li, Hui; Hou, Yu; Huang, Yongxiu; Xie, Mingling; Huang, Zhen; Zhang, Yali; Ma, Yan; Wu, Guixian; Xu, Shuangnian; Chen, Jieping

doi:10.1155/2021/1929357

Cited by 5 publications

(11 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CD56, which is also known as NCAM1, is abnormally expressed in 15 to 20% of patients with AML and is associated with reduced complete remission rates, high relapse rates and poor OS [ 17 ]. Laboratory research has shown that CD56 expression promotes leukemogenesis and confers drug resistance in AML [ 9 ].…”

Section: Discussionmentioning

confidence: 99%

“…Therefore, it is very important to identify a new antigen marker that is highly expressed on the surface of AML cells and related to the clinical outcome. CD56, which is also known as NCAM1, is abnormally expressed in 15 to 20% of patients with AML and is associated with reduced complete remission rates, high relapse rates and poor OS [17]. Laboratory research has shown that CD56 expression promotes leukemogenesis and confers drug resistance in AML [9].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluating the prognostic value of CD56 in pediatric acute myeloid leukemia

Liang

Peng²,

Li³

et al. 2022

BMC Cancer

View full text Add to dashboard Cite

Background Many cytogenetic changes and gene mutations are associated with acute myeloid leukemia (AML) survival outcomes. CD56 is related to poor prognosis when expressed in adult AML patients. However, the prognostic value of CD56 in children with AML has rarely been reported. In this research, we aimed to evaluate the prognostic value of CD56 in childhood AML. Methods The present retrospective study included 145 newly diagnosed pediatric patients with de novo AML (excluding AML-M3) in two hospitals between January 2015 and April 2021. Results The total median (range) age was 75 (8–176) months, and the median follow-up time was 35 months. No significant difference in the 3-year overall survival rate was noted between the CD56-positive and CD56-negative groups (67.0% vs. 79.3%, P = 0.157) who received chemotherapy. However, among high-risk patients, the CD56-positive group had a worse overall survival rate and event-free survival rate (P < 0.05). Furthermore, among high-risk patients, the CD56-positive group had higher relapse and mortality rates than the CD56-negative group (P < 0.05). Conclusions CD56 represents a potential factor of poor prognosis in specific groups of children with AML and should be considered in the risk stratification of the disease. Given the independent prognostic value of CD56 expression, we should consider integrating this marker with some immunophenotypic or cytogenetic abnormalities for comprehensive analysis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Evaluating the prognostic value of CD56 in pediatric acute myeloid leukemia

Liang

Peng²,

Li³

et al. 2022

BMC Cancer

View full text Add to dashboard Cite

show abstract

“…CD56 expression is considered an indicator of poor prognosis in patients with acute myeloid leukemia, anaplastic large cell lymphoma and diffuse large B-cell lymphoma. [25][26][27] However, Wang et al did show that CD56-negative extranodal NK/T cell lymphoma had significantly inferior survival outcomes. 28 The CD56negative patient (Patient 1) in our study was alive for 31.6 months until the last follow-up.…”

Section: Discussionmentioning

confidence: 99%

Survival Analysis of Hepatosplenic T Cell Lymphoma: A Population-Based Study Using SEER

Li¹,

Chen²,

Zuo³

et al. 2021

IJGM

View full text Add to dashboard Cite

“…Sci. 2023, 24, x FOR PEER REVIEW Cheng et al [48] Lin et al [49] Zhang et al [50] Depreter et al [51] Rostami et al [52] Steger et al [53] Willier et al [54] Chashchina et al [55] Churchill et al [56] Wang et al [57] Sun et al [58] Red circles indicate a risk of bias; Green circles indicate no Lin et al [33] Table 3. Risk of bias and quality assurance using the QUADAS-2 system of article assessment.…”

Section: Dos Santos Et Al [23]mentioning

confidence: 99%

“…Cheng et al [48] Lin et al [49] Zhang et al [50] Depreter et al [51] Rostami et al [52] Steger et al [53] Willier et al [54] Chashchina et al [55] Churchill et al [56] Wang et al [57] Sun et al [58] Red circles indicate a risk of bias; Green circles indicate no risk of bias, was identified. Cheng et al [48] Lin et al [49] Zhang et al [50] Depreter et al [51] Rostami et al [52] Steger et al [53] Willier et al [54] Chashchina et al [55] Churchill et al [56] Wang et al [57] Sun et al [58] Red circles indicate a risk of bias; Green circles indicate no risk of bias, was identified. Darwish et al [25] Xiao et al [26] Wang et al [27] Xu et al [28] Haubner et al [29] Abdellateif et al [30] Int.…”

Section: ]mentioning

confidence: 99%

A Direct Comparison, and Prioritisation, of the Immunotherapeutic Targets Expressed by Adult and Paediatric Acute Myeloid Leukaemia Cells: A Systematic Review and Meta-Analysis

Morris

Ghazi

Fletcher

et al. 2023

IJMS

View full text Add to dashboard Cite

Acute myeloid leukaemia (AML) is characterized by impaired myeloid differentiation resulting in an accumulation of immature blasts in the bone marrow and peripheral blood. Although AML can occur at any age, the incidence peaks at age 65. The pathobiology of AML also varies with age with associated differences in incidence, as well as the frequency of cytogenetic change and somatic mutations. In addition, 5-year survival rates in paediatrics are 60–75% but fall to 5–15% in older AML patients. This systematic review aimed to determine whether the altered genes in AML affect the same molecular pathways, indifferent of patient age, and, therefore, whether patients could benefit from the repurposing drugs or the use of the same immunotherapeutic strategies across age boundaries to prevent relapse. Using a PICO framework and PRISMA-P checklist, relevant publications were identified using five literature databases and assessed against an inclusion criteria, leaving 36 articles, and 71 targets for therapy, for further analysis. QUADAS-2 was used to determine the risk of bias and perform a quality control step. We then priority-ranked the list of cancer antigens based on predefined and pre-weighted objective criteria as part of an analytical hierarchy process used for dealing with complex decisions. This organized the antigens according to their potential to act as targets for the immunotherapy of AML, a treatment that offers an opportunity to remove residual leukaemia cells at first remission and improve survival rates. It was found that 80% of the top 20 antigens identified in paediatric AML were also within the 20 highest scoring immunotherapy targets in adult AML. To analyse the relationships between the targets and their link to different molecular pathways, PANTHER and STRING analyses were performed on the 20 highest scoring immunotherapy targets for both adult and paediatric AML. There were many similarities in the PANTHER and STRING results, including the most prominent pathways being angiogenesis and inflammation mediated by chemokine and cytokine signalling pathways. The coincidence of targets suggests that the repurposing of immunotherapy drugs across age boundaries could benefit AML patients, especially when used in combination with conventional therapies. However, due to cost implications, we would recommend that efforts are focused on ways to target the highest scoring antigens, such as WT1, NRAS, IDH1 and TP53, although in the future other candidates may prove successful.

show abstract

Prognostic Significance of CD56 Antigen Expression in Patients with De Novo Non‐M3 Acute Myeloid Leukemia

Cited by 5 publications

References 41 publications

Evaluating the prognostic value of CD56 in pediatric acute myeloid leukemia

Evaluating the prognostic value of CD56 in pediatric acute myeloid leukemia

Survival Analysis of Hepatosplenic T Cell Lymphoma: A Population-Based Study Using SEER

A Direct Comparison, and Prioritisation, of the Immunotherapeutic Targets Expressed by Adult and Paediatric Acute Myeloid Leukaemia Cells: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About